Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 174-179 , September 2010

Methadone use among HIV-positive injection drug users in a Canadian setting

  • Tyler Pettes

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Canada
    • ,
  • Evan Wood, M.D., Ph.D

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Canada
    • Division of AIDS, Department of Medicine, University of British Columbia, Canada
    • ,
  • Silvia Guillemi, M.D

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Canada
    • ,
  • Calvin Lai, M.Math

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Canada
    • ,
  • Julio Montaner, M.D

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Canada
    • Division of AIDS, Department of Medicine, University of British Columbia, Canada
    • ,
  • Thomas Kerr, Ph.D

      Affiliations

    • British Columbia Centre for Excellence in HIV/AIDS, Canada
    • Division of AIDS, Department of Medicine, University of British Columbia, Canada
    • Corresponding Author InformationCorresponding author. Urban Health Research Initiative, BC Centre for Excellence in HIV/AIDS, 608 - 1081 Burrard Street, Vancouver BC, Canada V6Z 1Y6. Fax: +1 604 806 9044.

Received 2 November 2009 ,Revised 22 April 2010 ,Accepted 3 May 2010.

References 

  1. American Society of Addiction Medicine . Public policy statement on national drug policy. Journal of Addictive Diseases. 1994;13:231–234
  2. Ball J, Ross A. The effectiveness of methadone maintenance treatment: Patients, programs, services and outcomes. New York: Springer-Verlag; 1991;
  3. Clarke, S., Keenan, E., Ryan, M., Barry, M., & Mulcahy, F. (2002). Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read, 12, 305–307, 312–306.
  4. Condelli WS, Dunteman GH. Exposure to methadone programs and heroin use. American Journal of Drug and Alcohol Abuse. 1993;19:65–78
  5. Corsi KF, Kwiatkowski CF, Booth RE. Predictors of methamphetamine injection in out-of-treatment IDUs. Substance Use & Misuse. 2009;44:332–342
  6. Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, et al. Risk factors for elevated HIV incidence among aboriginal injection drug users in Vancouver. Canadian Medical Association Journal. 2003;168:19–24
  7. Davstad I, Stenbacka M, Leifman A, Romelsjo A. An 18-year follow-up of patients admitted to methadone treatment for the first time. Journal of Addictive Diseases. 2009;28:39–52
  8. Des Jarlais DC, Paone D, Milliken J, Turner CF, Miller H, Gribble J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: A quasi-randomised trial. Lancet. 1999;353:1657–1661
  9. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine. 1969;280:1372–1375
  10. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews. 2003;CD002208
  11. Goldstein A. Heroin addiction: Neurobiology, pharmacology, and policy. Journal of Psychoactive Drugs. 1991;23:123–133
  12. In:  Greenstein RA,  Fudala PJ,  O'Brien CP editor. Alternative pharmacotherapies for opiate addiction. Baltimore: Williams and Wilkins; 1997;
  13. Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug and Alcohol Dependence. 2007;87:39–45
  14. Kerr T, Marsh D, Li K, Montaner J, Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug and Alcohol Dependence. 2005;80:329–335
  15. Kerr T, Wood E, Grafstein E, Ishada T, Shannon K, Lai C, et al. High rates of primary care and emergency department use among injection drug users in Vancouver. Journal Public Health. 2004;27:62–66
  16. Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103:1484–1492
  17. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS. 2007;21:564–574
  18. Marsh DC, Fair BR. Addiction treatment in Vancouver. The International Journal on Drug Policy. 2006;17:137–141
  19. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug and Alcohol Depend. 2006;84:188–194
  20. Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. Canadian Medical Association Journal. 2001;165:415–420
  21. Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study. Addiction. 2009;103(11):1828–1836
  22. Senay E, Uchtenhagen A. Methadone in the treatment of opioid dependence: A review of world literature. In:  Arif A,  Westermeyer J editor. Methadone maintenance in the management of opioid dependence. New York: Prager; 1990;
  23. Shah NG, Celentano DD, Vlahov D, Stambolis V, Johnson L, Nelson KE, et al. Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. [In Process Citation] AIDS. 2000;14:2035–2043
  24. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). International Journal on Drug Policy. 2007;18:262–270
  25. Wall R, Rehm J, Fischer B, Brands B, Gliksman L, Stewart J, et al. Social costs of untreated opioid dependence. Journal of Urban Health. 2000;77:688–722
  26. Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300:550–554
  27. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Annals of Internal Medicine. 2003;139:810–816
  28. Wood E, Kerr T, Palepu A, Zhang R, Strathdee SA, Tyndall MW, et al. Slower uptake of HIV antiretroviral therapy among aboriginal injection drug users. Journal of Infection. 2006;52:233–236
  29. Wood E, Li K, Palepu A, Marsh DC, Schechter MT, Hogg RS, et al. Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users. Substance Use & Misuse. 2005;40:1153–1167
  30. Wood E, Montaner JS, Li K, Barney L, Tyndall MW, Kerr T. Rate of methadone use among aboriginal opioid injection drug users. Canadian Medical Association Journal. 2007;177:37–40
  31. Wood E, Montaner JS, Li K, Zhang R, Barney L, Strathdee SA, et al. Burden of HIV infection among aboriginal injection drug users in Vancouver, British Columbia. American Journal of Public Health. 2008;98:515–519

PII: S0740-5472(10)00095-4

doi: 10.1016/j.jsat.2010.05.001

Journal of Substance Abuse Treatment
Volume 39, Issue 2 , Pages 174-179 , September 2010

Article Tools